Biology of anti-angiogenic therapy-induced thrombotic microangiopathy

Seminars in Nephrology

Volumn 30, Issue 6, 2010, Pages 582-590

  Eremina, Vera ^a   Quaggin, Susan E ^a,b,c  

^a MOUNT SINAI HOSPITAL   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Anti VEGF therapy; Endothelial cells; Glomerulus; TMA

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; AXITINIB; BEVACIZUMAB; CALCINEURIN INHIBITOR; IMC 1121B; IMC 18F 1; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; RAMUCIRUMAB; RANIBIZUMAB; SEMAXANIB; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ARTICLE; DISEASE COURSE; DISEASE PREDISPOSITION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; GENETIC MODEL; GLOMERULOPATHY; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; INCIDENCE; KIDNEY CARCINOMA; KIDNEY FAILURE; NEPHROTIC SYNDROME; NEPHROTOXICITY; NONHUMAN; PATHOGENESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN TARGETING; PROTEINURIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; KIDNEY GLOMERULUS; MICE; MODELS, ANIMAL; PROTEINURIA; RENAL INSUFFICIENCY; SIGNAL TRANSDUCTION; THROMBOTIC MICROANGIOPATHIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 78649932949     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2010.09.006     Document Type: Article

References (55)

1. Connolly D.T., Olander J.V., Heuvelman D., Nelson R., Monsell R., Siegel N., et al. Human vascular permeability factor. Isolation from U937 cells. J Biol Chem 1989, 264:20017-20024.
2. Leung D.W., Cachianes G., Kuang W.J., Goeddel D.V., Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989, 246:1306-1309.
3. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285:1182-1186.
4. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002, 2:795-803.
5. Kook D., Wolf A., Kreutzer T., Neubauer A., Strauss R., Ulbig M., et al. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema. Retina 2008, 28:1053-1060.
6. Yoo S.A., Kwok S.K., Kim W.U. Proinflammatory role of vascular endothelial growth factor in the pathogenesis of rheumatoid arthritis: prospects for therapeutic intervention. Mediators Inflamm 2008, 2008:129873.
7. Avery R.L. New treatments for age-related macular degeneration. Lancet 2007, 370:1479-1480. author reply 1480.
8. Tischer E., Mitchell R., Hartman T., Silva M., Gospodarowicz D., Fiddes J.C., et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 1991, 266:11947-11954.
9. Bates D.O., Cui T.G., Doughty J.M., Winkler M., Sugiono M., Shields J.D., et al. VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res 2002, 62:4123-4131.
10. Woolard J., Wang W.Y., Bevan H.S., Qiu Y., Morbidelli L., Pritchard-Jones R.O., et al. VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res 2004, 64:7822-7835.
11. Harper S.J., Bates D.O. VEGF-A splicing: the key to anti-angiogenic therapeutics?. Nat Rev Cancer 2008, 8:880-887.
12. Sison K., Eremina V., Baelde H., Min W., Hirashima M., Rossant J., et al. Glomerular structure and function require paracrine, not autocrine, VEGF-VEGFR-2 signaling. J Am Soc Nephrol 2010 Aug 5, [Epub ahead of print].
13. Fong G.H., Rossant J., Gertsenstein M., Breitman M.L. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995, 376:66-70.
14. Quinn T.P., Peters K.G., De Vries C., Ferrara N., Williams L.T. Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. Proc Natl Acad Sci U S A 1993, 90:7533-7537.
15. Gerber H.P., Malik A.K., Solar G.P., Sherman D., Liang X.H., Meng G., et al. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 2002, 417:954-958.
16. Sawano A., Iwai S., Sakurai Y., Ito M., Shitara K., Nakahata T., et al. Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocyte-macrophages in humans. Blood 2001, 97:785-791.
17. Ferrara N. Vascular endothelial growth factor. Eur J Cancer 1996, 32A:2413-2422.
18. Shalaby F., Rossant J., Yamaguchi T.P., Gertsenstein M., Wu X.F., Breitman M.L., et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 1995, 376:62-66.
19. Tchaikovski V., Fellbrich G., Waltenberger J. The molecular basis of VEGFR-1 signal transduction pathways in primary human monocytes. Arterioscler Thromb Vasc Biol 2008, 28:322-328.
20. Niida S., Kondo T., Hiratsuka S., Hayashi S., Amizuka N., Noda T., et al. VEGF receptor 1 signaling is essential for osteoclast development and bone marrow formation in colony-stimulating factor 1-deficient mice. Proc Natl Acad Sci U S A 2005, 102:14016-14021.
21. Eremina V., Sood M., Haigh J., Nagy A., Lajoie G., Ferrara N., et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003, 111:707-716.
22. Eremina V., Cui S., Gerber H., Ferrara N., Haigh J., Nagy A., et al. VEGF-A signaling in the podocyte-endothelial compartment is required for mesangial cell migration and survival. J Am Soc Nephrol 2006, 17:724-735.
23. Eremina V., Jefferson J.A., Kowalewska J., Hochster H., Haas M., Weisstuch J., et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008, 358:1129-1136.
24. Ryan A.M., Eppler D.B., Hagler K.E., Bruner R.H., Thomford P.J., Hall R.L., et al. Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody. Toxicol Pathol 1999, 27:78-86.
25. Association of microangiopathic haemolytic anemia (MAHA) with the combined use of AVASTIN (bevacizumab) and sunitinib malate in metastatic renal cell carcinoma Health Canada. http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/_2008/avastin_nth-aah-eng.php.
26. Gerber H.P., Hillan K.J., Ryan A.M., Kowalski J., Keller G.A., Rangell L., et al. VEGF is required for growth and survival in neonatal mice. Development 1999, 126:1149-1159.
27. Ostendorf T., Kunter U., Eitner F., Loos A., Regele H., Kerjaschki D., et al. VEGF(165) mediates glomerular endothelial repair. J Clin Invest 1999, 104:913-923.
28. Yang J.C., Haworth L., Sherry R.M., Hwu P., Schwartzentruber D.J., Topalian S.L., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003, 349:427-434.
29. Escudier B., Pluzanska A., Koralewski P., Ravaud A., Bracarda S., Szczylik C., et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007, 370:2103-2111.
30. Rixe O., Bukowski R.M., Michaelson M.D., Wilding G., Hudes G.R., Bolte O., et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 2007, 8:975-984.
31. Roncone D., Satoskar A., Nadasdy T., Monk J.P., Rovin B.H. Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma. Nat Clin Pract Nephrol 2007, 3:287-293.
32. Frangie C., Lefaucheur C., Medioni J., Jacquot C., Hill G.S., Nochy D. Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma. Lancet Oncol 2007, 8:177-178.
33. Stokes M.B., Erazo M.C., D'Agati V.D. Glomerular disease related to anti-VEGF therapy. Kidney Int 2008, 74:1487-1491.
34. Izzedine H., Brocheriou I., Deray G., Rixe O. Thrombotic microangiopathy and anti-VEGF agents. Nephrol Dial Transplant 2007, 22:1481-1482.
35. Bollee G., Patey N., Cazajous G., Robert C., Goujon J.M., Fakhouri F., et al. Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib. Nephrol Dial Transplant 2009, 24:682-685.
36. Stillman I.E., Karumanchi S.A. The glomerular injury of preeclampsia. J Am Soc Nephrol 2007, 18:2281-2284.
37. Maynard S.E., Min J.Y., Merchan J., Lim K.H., Li J., Mondal S., et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003, 111:649-658.
38. Levine R.J., Maynard S.E., Qian C., Lim K.H., England L.J., Yu K.F., et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004, 350:672-683.
39. Levine R.J., Lam C., Qian C., Yu K.F., Maynard S.E., Sachs B.P., et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006, 355:992-1005.
40. Feldman D.R., Baum M.S., Ginsberg M.S., Hassoun H., Flombaum C.D., Velasco S., et al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2009, 27:1432-1439.
41. Patel T.V., Morgan J.A., Demetri G.D., George S., Maki R.G., Quigley M., et al. A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib. J Natl Cancer Inst 2008, 100:282-284.
42. Miller K.D., Chap L.I., Holmes F.A., Cobleigh M.A., Marcom P.K., Fehrenbacher L., et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005, 23:792-799.
43. Izzedine H., Brocheriou I., Rixe O., Deray G. Interstitial nephritis in a patient taking sorafenib. Nephrol Dial Transplant 2007, 22:2411.
44. George B.A., Zhou X.J., Toto R. Nephrotic syndrome after bevacizumab: case report and literature review. Am J Kidney Dis 2007, 49:e23-e29.
45. Nasr S.H., Snyder R.W., Bhagat G., Markowitz G.S. Chronic lymphocytic leukemia and cryoglobulinemic glomerulonephritis. Kidney Int 2007, 71:93.
46. Advani A., Kelly D.J., Advani S.L., Cox A.J., Thai K., Zhang Y., et al. Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions. Proc Natl Acad Sci U S A 2007, 104:14448-14453.
47. Sugimoto H., Hamano Y., Charytan D., Cosgrove D., Kieran M., Sudhakar A., et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem 2003, 278:12605-12608.
48. Lee S., Chen T.T., Barber C.L., Jordan M.C., Murdock J., Desai S., et al. Autocrine VEGF signaling is required for vascular homeostasis. Cell 2007, 130:691-703.
49. Lee T.H., Seng S., Sekine M., Hinton C., Fu Y., Avraham H.K., et al. Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1. PLoS Med 2007, 4:e186.
50. Guan F., Villegas G., Teichman J., Mundel P., Tufro A. Autocrine VEGF-A system in podocytes regulates podocin and its interaction with CD2AP. Am J Physiol Renal Physiol 2006, 291:F422-F428.
51. Maharaj A.S., Saint-Geniez M., Maldonado A.E., D'Amore P.A. Vascular endothelial growth factor localization in the adult. Am J Pathol 2006, 168:639-648.
52. Jonkers I.J., van Buren M. Nephrotic-range proteinuria in a patient with a renal allograft treated with sorafenib for metastatic renal-cell carcinoma. Clin Exp Nephrol 2009, 13:397-401.
53. Zheng X.L., Sadler J.E. Pathogenesis of thrombotic microangiopathies. Annu Rev Pathol 2008, 3:249-277.
54. Delvaeye M., Noris M., De Vriese A., Esmon C.T., Esmon N.L., Ferrell G., et al. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med 2009, 361:345-357.
55. Schneider B.P., Wang M., Radovich M., Sledge G.W., Badve S., Thor A., et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008, 26:4672-4678.